Association Europenne des Spcialits Pharma-ceutiques Grand Public

Association of the European Self-Medication Industry

Europischer Verband der Arzneimittel-Hersteller

1964-2014

5years

2 aesgp.eu

Table of contents

Message from the President 3

Message from the Director General 4

History 5

Mission 12

Policy recommendations 13

AESGP Members 14

How AESGP works 16

Stakeholder collaboration 18

Publications 20

Annual Meetings 24

Past Presidents and Directors General 26

AESGP Euro OTC News 27

50 Years AESGP 3

Message from the President

The year 2014 is an important milestone in the history of the Association of the European Self-Medication Industry (AESGP); its 50th anniversary. Initiated in the early 1960s by just three companies, the association has grown to become the official voice of the consumer healthcare industry in Europe. It represents national associations and directly or indirectly - through the national associations - more than 2000 companies producing non-prescription medicines, food supplements and self-care medical devices

AESGP celebrates its 50th anniversary having achieved the key objectives set at the time of its establishment:

There is a recognised and established distinction between prescription and no-prescription medicines across Europe

Communication with citizens and the provision of information through advertising are allowed

Free pricing for manufacturers is the standard practice in nearly all European countries, with European Union policy initiatives unequivocally acknowledging that free pricing for manufacturers allows the development of a competitive market environment, rendering price control measures for non-prescription medicines unnecessary.

The realisation of the full potential of self-care will only be possible when European citizens are empowered and well informed about different products and their appropriate use. In the years to come, ensuring the right of all European citizens to self-care and have access to information and innovative, effective, safe and high quality products will remain a guiding principle for AESGP. As before, the association will pursue this objective highly committed, with responsibility and integrity.

Hans Regenauer, AESGP President

4 aesgp.eu

Message from the Director General

AESGP has dedicated the past 50 years to advancing the practice of self-care in Europe. Throughout this time, the association strives to pursue its objectives by remaining faithful to the fundamental principles of professional competence and comprehensive service to members.

In its work, AESGP relies on the close cooperation with European authorities and other stakeholders. It is critical that European bodies have a good understanding of the sectors specificities and a grasp on the actual impact of different decisions made on the self-care market. Close relationship with different stakeholder groups has been one of the most valuable and rewarding aspects of the associations work. Gaining a good understanding of the interests and concerns of others has allowed AESGP to reassess its own positioning on different issues and to work together with other stakeholders to achieve common goals.

The same principle applies in our internal work with our members. The well organised network of associations and companies is the driving force of the association. It allows us to comprehensively assess the environment, reflect on developments and take informed political decisions. The close collaboration of the AESGP membership is the cornerstone of the associations success and where we can attribute the significant, tangible results for the entire consumer healthcare sector achieved through our political work on a national, European and global level.

Hubertus Cranz, AESGP Director General

50 Years AESGP 5

History

Establishment

In 1963, a small group of representatives, primarily from the companies Miles, Nicholas and Vick, came together under the Chairmanship of Ben McClure of Vick International to discuss the possible need for collective action in light of the many threats and opportunities for the self-care industry, which was then referred to as the Proprietary Medicines Industry.

A year later, on 3 February 1964, the Association Europenne des Spcialits Pharmaceutiques Grand Public, AESGP was founded in Paris.

Vision

At a time when self-care was considered to be either synonymous with home remedies or potentially unnecessary due to the expected advancements of the medical profession, the founders of the Association envisioned a strong self medication sector:

A dynamic and innovative part of the pharmaceutical industry that would support increasingly empowered citizens to self-care.

Restaurant bill from the inaugural meeting of the AESGP founders.

1961 1962 1963 1964

6 aesgp.eu

1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977

In the early years following its establishment, AESGP became the key liaison between the self-care industry and the European Community bodies.

The growth of the sector in Europe was supported by AESGP, that was steadily developing in terms of membership and increased involvement in the European healthcare dialogue.

Directive 65/65/EECFirst European piece of legislation for pharmaceuticals. It provided the definition of a medicinal product, introduced the requirement for an authorisation prior to commercialisation and set out labeling provisions.

By 1967 AESGP numbered 9 national member associations and represented more than 300 companies.

Committee for Proprietary Medicinal Products set up to facilitate the principle of mutual recognition of marketing authorisations.

Testing requirements introduced.

AESGP, together with the Associations from the United States and Canada, was one of the founding members, in April 1970, of the World Federation of Proprietary Medicines Manufacturers (WFPMM) that would later on become WSMI.

Reclassifications in Europe 1976: Antihistamines

50 Years AESGP 7

In the late 70s and early 80s the critical role individuals could and should play in maintaining their health was starting to be recognised and supported.

WHO - Declaration of Alma-Ata

() people have the right and duty to participate individually and collectively in the planning and implementation of their healthcare

WHO, International Conference on Primary Health Care, Alma-Ata, April 1978

1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990

AESGP obtains the status of non-governmental organisation with the Council of Europe.

AESGP Annual Meeting at the premises of the World Health Organisation in Copenhagen 1986

1981: Benzoyl peroxide 1983: Ibuprofen, Loperamide 1986: Hydrocortizone 1988: Nicotine

8 aesgp.eu

1991 1992 1993 1994 1995

The 90s were marked by significant developments and political divisions of the past giving their place to a united continent facing future with the promise of progress.Important changes were also observed in the European regulatory framework on pharmaceuticals, with a recognition of the role of non-prescription medicines.

Reclassifications in Europe 1993: Aciclovir 1995: Fluconazole

New legislation addressing: The classification status of medicinal

products, distinguishing between prescription and non-prescription medicines

Advertising, allowing the advertising of non-prescription medicines to the public

Patient information (labelling and package leaflets)

Wholesale distribution Homeopathic medicines

AESGP implements a proactive policy for the development of a distinct non-prescription medicines sector in Eastern European countries.

Related activities are supported by the publication of the policy document Developing Self-Medication in Central and Eastern Europe in Russian, Bulgarian, Czech, Hungarian, Polish and Ukrainian.

The European Medicines Agency is established, and the centralised procedure for the authorisation and supervision of medicinal products comes into operation.

50 Years AESGP 9

1996 1997 1998 1999 2000 2001

AESGP and European doctors associations produce with the support of the European Commission the information document on What is self-medication (see more under Stakeholder collaboration, p.18).

AESGP Food Supplements Committee established

2001/83/ECConsolidation of the European

pharmaceutical legislation proposed.

AESGP conducts study to improve patient information leaflets in order to make them more readable and useful to patients following request by the European Commission.

AESGP conducts study on herbal medicines commissioned by the European Commission leading to the foundation of Directive 2004/24/EC.

1997: Ranitidine 1998: Domperidone 2000: Cimetidine

10 aesgp.eu

2002 2003 2004 2005 2006 2007 2008

Further EU enlargement and consequent harmonisation of rules for medicines in European countries has been a main recent development.Patient empowerment has also been a major trend in healthcare in the past years.

2001: Levonorgestol, Triamcilonone 2002: Loratadine 2003: Omeprazole

G10 reportThe High Level Group on innovation and provision of medicines, a European Commission policy initiative, publishes report making significant policy recommendations for non-prescription medicines, noting that no price control is required for these products.

Regulation 726/04, Title IVA revision of the European marketing authorisation procedures in 2004 gives non-prescription medicines the possibility to use the centralised procedure.

Directive 2004/24/ECLegislation on herbal medicines, harmonising definition of traditional herbal medicinal products which could benefit from simplified procedure and setting up a Committee on Herbal Medicinal Products within the EMA.

Development of information policy - European Commission funded AESGP study and presents indications for self-care (see page 21).

European Union enlargement with ten new member states

50 Years AESGP 11

2009 2010 2011 2012 2013 2014

A policy initiative by AESGP identifies key areas requiring regulatory improvement in order to support the development of the self-care sector.

Reclassifications through the centralised procedure2009: Orlistat , Pantoprazole 2013: Esomeprazole

Process on Corporate ResponsibilityThe European Commission launches a 3-year policy initiative examining Ethics and Transparency in the pharmaceutical sector and Access to medicines in Europe and Africa.A dedicated multi-stakeholder project group on non-prescription medicines examines how to improve uptake of medicines following reclassification to non-prescription status.

AESGP Medical Devices Committee established Addressing the growth of the self-care medical devices sector and the introduction of new European legislation on medical devices, AESGP sets up a new Committee on self-care medical devices.

2004: Simvastatin 2005: Chloramphenicol

Agreement on elements of

success

Facilitating innovation

Early stakeholder involvement

Collaboration and

engagement

Training and education

Access to information

How to achieve good governance

S e l f - c a r e : T h e f i r s t c h o i c e i n h e a l t h c a r e7 avenue de Tervuren, 1040 Brussels, Belgium | Tel: + 32 2 735 51 30 | Fax: + 32 2 735 52 22 | info@aesgp.eu | www.aesgp.eu

12 aesgp.eu

Mission

The mission of AESGP is to ensure a sustainable positive development of the self-care industry.

AESGP is working to achieve this by focusing on the following strategic objectives:

To ensure that self-care plays an increasingly valuable role in healthcare as a positive and cost-effective contributor to the health and well-being of Europes citizens.

To ensure that consumers can be well informed on the availability of self-care products, e.g. through advertising, presentation in pharmacies and through the development of brands which they can trust and rely on.

To ensure recognition of the self-care industrys role as a reliable and trustworthy provider of self-care solutions.

To achieve the adoption and implementation of a balanced and proportionate regulatory and economic framework that facilitates innovation and rapid market access for the widest range of self-care products in a consistent way across Europe.

To promote a competitive environment for the self-care market, supporting free pricing by manufacturers for self-care products.

Policy recommendations presented in the AESGP publication: Self-Care: A Winning Solution

50 Years AESGP 13

A balanced benefit-risk assessment for Marketing Authorisations

Evaluation procedures for non-prescription medicines should take into consideration the benefits of the use of products in the practice of responsible self-care and not focus exclusively on risks regardless of whether or not these can be mitigated. A balanced assessment can better serve the interests of European citizens.

Facilitating the switch process for appropriate ingredients

A systematic, comprehensive approach to the reclassification of prescription medicines and active ingredients that takes into account the specific characteristics of self-care products and the need to reward investments is necessary to reduce the inequalities between European citizens in different member states and to take full advantage of the potential of self-care.

Detailed product information

Citizens should have access to detailed product information and instructions of use in order to be able to use self-care in a safe and responsible manner and thus improve their health.

Comprehensive advertising

Consumers should be able to get information through the communication channels they prefer without restrictions, be it in specialised written press, public displays, TV or digital media. Clear self-governing principles should be agreed in all EU member states.

Better visibility

Increased visibility of products at the point of sale should be assured to give consumers the time to make an informed and responsible choice concerning their self-care treatment.

Consistent branding

Consistent branding using traditional, wellknown brands should be encouraged in order to help individuals navigate through available products.

Competitive pricing

Industry should be allowed to engage in competitive pricing in order for the self-care market to function without distortions and for individuals to be able to reap all the benefits of a free market.

Rigorous research on the role of self-care

Stakeholders and institutions (e.g. the European Commission) involved in research should commission research on the role, importance and efficiency of self-care in Europes healthcare systems in order to define appropriate regulation and incentives.

Challenge for the future - AESGP Policy Recommendations

Policy recommendations presented in the AESGP publication: Self-Care: A Winning Solution

14 aesgp.eu

AESGP Members

AESGP is the voice of more than 2000 companies operating in the consumer healthcare sector in Europe, affiliated with AESGP directly or indirectly through the national associations. The AESGP constituency includes the main multinational companies as well as the European SMEs of the sector.

Austria

Denmark

The DanishAssociation of the Pharmaceutical Industry

Germany

Ireland

Netherlands

ASSOSALUTEAssociazione nazionale farmaci di automedicazione

Belgium

Czech Republic

France

Hungary

Lithuania

NEPROFARM

Neprofarm

NEPROFARM

Belgium

Croatia

Finland

Greece

Italy

National associations

50 Years AESGP 15

Portugal

Sweden

Poland

Spain

United-KingdomTurkey

GSKBoehringer Ingelheim

MerzMerck

PGTPfizer

Farbe/colour:PANTONE 288 CV

Reckitt Benckiser Sanofi

Norway

Slovenia

Switzerland

Bayer

Johnson-&-Johnson

Novartis

International companies (with a Board seat)

16 aesgp.eu

How AESGP works

AESGP brings the consumer healthcare industry into contact with policy makers and other stakeholders at the European level. Support on the national level is also provided when requested by national organisations.

The Association is regularly consulted on healthcare issues and in particular pharmaceutical, food and health policy matters in Europe. AESGP comments and input in various consultations and policy initiatives provide a clear view of the self-care sectors positions to European Union institutions and contribute to the European health dialogue.

The AESGP Board is composed of representatives of member associations and international companies and decides on the overall positioning of the association and important policy issues.

Memberassociations

Expertsfrom memberassociations

Commitees

Board

Membercompanies

Expertsfrom member

companies

50 Years AESGP 17

AESGP Committees are the operational branches of the association.

Based on the strategic guidance provided by the Board, AESGP Committees follow closely and in depth developments in their respective areas and implement policies of the association.

The Committees also function as platforms for sharing information on national practices between AESGP members, with a view to studying and promoting best practices in the self-care sector in Europe.

All work is coordinated by the AESGP offices in Brussels.

Worldwide

AESGP represents its members in the World Self-Medication Industry (WSMI).

As a Non-Governmental Organisation (NGO) in official relations with the World Health Organization, WSMI contributes to WHOs Public Health goals through specialised expertise. WSMI also represents the industry in other international organisations, such as ICH, WIPO, Codex Alimentarius and internationl health professionals organisations.

In close collaboration with WSMI, AESGP informs its members of all relevant developments taking place on a global level with a potential impact on Europe.

Commitees

EconomicAffairs/PR

Herbalmedicines

RegulatoryAffairs

FoodSupplements Medical

devices

18 aesgp.eu

Stakeholder collaboration

Over the past 50 years, AESGP has worked together with representative bodies of health professionals, patients and consumers in order to promote the practice of responsible self-care.

AESGP worked together with the European umbrella organisation of medical doctors, the Standing Committee of European Doctors (CPME), and the European organisations of medical specialists (UEMS) and general practitioners (UEMO) to develop an information document on self-medication in an initiative supported by the European Commission.

http://www.aesgp.eu/self-care

Working with other industry associationsAESGP also regularly works together with European umbrella associations representing other sections of (the pharmaceutical) industry to address jointly common issues faced in Europe.

AESGP is member of numerous institutional stakeholder groups

Health Policy Forum, eHealth Stakeholder Group, Process on Corporate Responsibility, Advisory Forum on the Food Chain and Animal and Plant Health , Working Groups on medical devices

European Commission

50 Years AESGP 19

AESGP and PGEU, the representative body of community pharmacists in Europe, expressed their commitment to cooperate to promote the practice of selfcare in a Charter of Collaboration signed in 1993 and renewed in 2004 and 2012.

The Charter acknowledges the key role of pharmacists in helping to ensure safe and effective use of non-prescription medicines. It also points to the role of the European self-medication industry in ensuring that innovative, safe products of high quality reach the European consumers.

Key commitments by the two associations include developing pharmacies into health centres within their communities, improving citizens knowledge of health care products, and communicating the benefits of self- care to regulators

AESGP also agreed with the European Association of Pharmaceutical Full-line Wholesalers (GIRP) to cooperate in the active presentation of non-prescription medicines in pharmacies and on the appropriate space/category management, taking into account and respecting national particularities and differences.

Both organisations recognise the importance of supporting the training of pharmacists and their staff in their role to communicate the benefits of non-prescription medicines; on the exchange of information on the supply and purchase of non-prescription medicines in the marketplace; and the need to ensure the most efficient way to supply non-prescription medicines to pharmacies.

1993

2004

2012

EMA Interested Party

EFSA Stakeholder Platform

EUnetHTA Stakeholder Platform

20 aesgp.eu

PublicationsE

co

no

mic

an

d L

ega

l Fr

am

ewo

rk

fo

r N

on

-Pr

esc

rip

tio

n M

edic

ines

Economic and Legal Framework for Non-Prescription Medicines

aesgp.eu

Association Europenne des Spcialits Pharmaceutiques Grand Public

Association of the European Self-Medication Industry

Europischer Verband der Arzneimittel-Hersteller

Self-care : The first choice in health care

2013

Economic and Legal Framework for non-

prescription medicines2013 - 18th Edition (648 pages)

Legal and Regulatory Framework for Herbal

Medicines2012 - 3rd Edition (354 pages)

Legal and Regulatory Framework for Food

Supplements2012 - 2nd Edition (401 pages)

The AESGP framework studies provide information on regulatory and market access provisions applicable to non-prescription medicines, herbal medicines and food supplements. Updated in collaboration mainly with WSMI and AESGP members, the studies are reference points for the sector and are often cited in various activities and publications by health authorities and other stakeholders.

1993 Self-Medication and the Pharmacist

1993 Developing Self-Medication in Central and Eastern Europe

1994 The Individual and Health Care: Added Value through Self-Medication

1996 The Value of the same Trademark for medicines with a different Legal Status

1997 CPME/AESGP Brochure on Self- Medication, supported by the European Commission

1997 The Visibility of Self-Medication Products in the Changing Pharmacy Environment

1998 Study on herbal medicinal products carried out by AESGP on behalf of the European Commission in English/German

1998 Medicines for Europe - A practical guide for the development, registration and marketing of medicinal products in the European Union

1998 Encouraging self-medication can reduce the healthcare cost burden: An Economic Analysis

1998 Improving Visibility of Self-Medication in Pharmacies

1999 Deregulation 2001-The Future of Medicine Regulation in Europe 2002 Common statement and Report of the PGEU-AESGP Workshop How appropriate presentation of non- prescription medicines enhances the role of the pharmacist

2002 Final report of the AESGP research project Development of an information policy for medicinal products

2004 The Economic and Public Health value of Self-medication

2008 Smart Regulation 2015

2012 Self-Care: A Winning Solution Annual reports highlighting AESGP activities and conference repots presenting meeting proceedings

http://www.aesgp.eu/publications

50 Years AESGP 21

Acne

Allergic conjunctivitis

Cold

Cold sores

Constipation

Cough

Diarrhoea

Emergency contraception

Erectile dysfunction

Fever

Flu prevention

Flu treatment

Haemorrhoids

Hayfever prevention

Arthritic pain

Caries prevention

Cholesterol lowering/lipid control

Dermatitis/eczema

Hayfever treatment

Male pattern baldness

Neural tube defect prevention

Bacterial conjunctivitis

Cystitis

Exercise-induced angina

Helminth infections

Lower urinary tract infection

Vaginal thrush

Anxiety

Asthma

Benign prostatic hypertrophy

Chronic insomnia

Depression (mild to moderate)

Diabetes (prevention of

complications and treatment

with oral agents)

Heart disease prevention

Herpes genitalis

Irritable bowel syndrome

Inflammatory bowel disease

Gout

Hypertension

Incontinence

Headache

Indigestion/heartburn

Insomnia (temporary)

Mild/moderate pain

Minor cuts and bruises

Mouth ulcers

Nausia from known causes

Smoking cessation

Sore throat

Symptoms of PMS

Topical bacterial infections

Weight management

Self-diagnosis & self-management

Recurrent/semi-chronic condition

Short-term use/acute condition

Long term use/ chronic condition

Doctor consultation & other health professional advice &patient self-management (with/without medical advice)

Indications for self-care. From the European Commission funded project conducted by AESGP: Information policy for non-prescription medicines (2002). The project examined different indications for self-care and presented the concept of collaborative care.

Malaria prevention

Menopause syndrome

Migraine

Obesity

Oral contraception

Osteoporosis prophylaxis

Psoriasis (mild)

Rheumatism

Venous leg ulcers

22 aesgp.eu

The significant economic value of self-medication was examined in different AESGP publications.

In 2004, an economic analysis identified the significant savings potential of self-medication by estimating the cost reductions of switching treatment from professional care to self-medication.

The publication Self-Care: A Winning Solution also addressed the public health and economic benefits of self-care, providing an overview of the outcomes of economic analyses at national level.

Each year, AESGP publishes online an overview of sales figures in Europe. The market data are provided mostly by national member associations and collected in the context of the preparation of the Economic and Legal Framework study for non prescription medicines.

http://www.aesgp.eu/facts-figures/market-data (open access)

Market data

50 Years AESGP 23

Ingredients

An online database of ingredients with non-prescription status in European and non-European countries is maintained by AESGP.

The database allows users to search ingredients by name in order to find their classification status in one or all available countries, while a search by parameter function allows users to get information on the classification status based of ingredients based on ATC levels 1 or 2, the year of switch, or by country.

Information in the database comes mainly from WSMI and AESGP member

Ingredients Directory2014

http://www.aesgp.eu/facts-figures/market-data (open access)

Data Bank data.aesgp.eu

AESGP Data Bank

The AESGP Data Bank is the online database launched in June 2014. It includes information previously found in the AESGP studies Economic and Legal Framework for non-prescription medicines and Legal and Regulatory Framework for Herbal Medicines.

Providing a variety of options to users and flexibility in the presentation of results, a key objective of the new database is to improve further the understanding of circumstances under which the practice of responsible self-care can be further encouraged and supported.

http://data.aesgp.eu (for registered users only) http://www.aesgp.eu/facts-figures/data-bank (registration information, open access)

associations and is updated regularly by AESGP. The outcomes of the March 2014 update are also presented in the publication AESGP Ingredients Directory.

24 aesgp.eu

Dublin

April 2628, 1978

June 57, 2002

Paris

November 1963 (foundation)

March 1965

December 2, 1966

June 1315, 1984

Annual Meetings Brussels October 30, 1967

October 3031, 1972

June 2729, 1990

Rome

November 2122, 1969

June 710, 1989 (together with the 9th

General Assembly of WFPMM)

June 810, 2011

June 69, 2001

London

Nov. 28 Dec. 1, 1971 (together with

the 1st WFPMM General Assembly)

February 2527, 1976

June 1416, 1994

June 35, 2014 (together with the 18th

WSMI General Assembly of WSMI)

Madrid

May 24, 1979

June 24, 2004

Amsterdam

April 2325, 1980

June 911, 1993

Funchal (Madeira)

May 2023, 1981

Cannes

October 2830, 1973

June 24, 1991

June 46, 2003

Barcelona

June 2426, 1992

Lisbon

June 710, 1995

June 57, 2013

Nice

June 68, 2012

50 Years AESGP 25

Lausanne

October 2425, 1968

Rome

November 2122, 1969

June 710, 1989 (together with the 9th

General Assembly of WFPMM)

June 810, 2011

June 69, 2001

Baden-Baden

October 1114, 1970

Vienna

October 34, 1974

May 2022, 1987

June 35, 2009

Geneva

March 2023, 1977 (together with

the 4th WFPMM General Assembly)

June 1517, 1988

June 13, 2005 (together with the

15th WSMI General Assembly)

Amsterdam

April 2325, 1980

June 911, 1993

Athens

May 1214, 1982

May 2023, 1998

June 79, 2006

Stockholm

June 810, 1983

June 1113, 2008

Munich

May 2931, 1985

Copenhagen

June 1113, 1986

Istanbul

May 29June 1, 1996

Budapest

June 1821, 1997

Berlin

June 912, 1999 (together with the

13th WSMI General Assembly)

Helsinki

May 1720, 2000

Warsaw

43. June 46, 2007

Dubrovnik

June 912, 2010

Munich

May 29-31, 1985

26 aesgp.eu

Jean Sall | France

Daniel Callewaert | Belgium

Hans W. Bach | Germany

Frederick G. Razzell | UK

Pierre Teisseire | France

D.N.A. McLure | UK

P. Giorgio Aquino | Italy

Anthony J. Jamison | UK

Antony B. Claasen | Netherlands

Jos-Antonio Perez-Espana | Spain

John R. Markley | UK

Heinz Schmidgall | Switzerland

Roberto Montanari | Italy

Berndt van Till | Netherlands

Hugues Lanrezac | France

Gerhard Stummerer | Austria

Alessandro Banchi | Italy

Albert Esteve | Spain

Hans van Zoonen | Switzerland

Hans Regenauer | Germany

Presidents and Directors General

Presidents

19631969

1 9 6 9 1 9 7 2

1 9 7 2 1 9 7 4

1 9 7 4 1 9 7 5

1 9 7 5 1 9 7 8

1 9 7 8 1 9 8 0

1 9 8 0 1 9 8 1

1 9 8 1 1 9 8 4

19841986

19861988

19881989

19891992

19921994

19941996

19961998

19982000

20002002

20022005

20052009

Since 2009

19641968

1 9 6 8 1 9 7 8

1 9 7 9 1 9 8 8

Since 1988

Directors General

Beverley Landrey

Pierre A. Visseur

Werner Sedlag

Hubertus Cranz

Logo 1964 - 1989

Logo 1989 - 1999 Logo 1999 - 2005 Logo introduced in 2005

50 Years AESGP 27

Directors General

AESGP Euro OTC News

Each month, AESGP publishes the AESGP Euro OTC News.

The newsletter is distributed to the AESGP constituency with the purpose of informing members about the latest developments on non-prescription medicines, food supplements and self-care medical devices.

The newsletter provides an overview of issues circulated in the course of the month before to Committee members. It also provides all the latest information on AESGP activities as well as news from members.

AESGP launched the first issue of its newsletter in 1990.Today, after more than 250 issues circulated in paper and electronic version, the AESGP Euro OTC News continues to serve as an informative and useful communication tool and is part of the AESGP service to its members.

Self Care: The first choice in healthcare

The Association of the European Self-Medication Industry is the representative body of the manufacturers

of non-prescription medicines, food supplements and self-care medical devices in Europe.

AESGP7 avenue de Tervuren

B-1040 Brussels, BelgiumTel: +32 2 735 51 30

Fax: +32 2 735 52 22E-mail: info@aesgp.eu

aesgp.eu